Investing.com - Nabriva Therapeutics reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Nabriva Therapeutics announced earnings per share of $-0.24 on revenue of $9.26M. Analysts polled by Investing.com anticipated EPS of $-0.19 on revenue of $10.1M.
Nabriva Therapeutics shares are down 17.57% from the beginning of the year and are trading at $0.4937 , down-from-52-week-high.They are under-performing the Nasdaq which is down 6.55% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings missed by Merck ADR on Thursday, March 3, 2022, who reported EPS of $0.4558 on revenue of $5.77B, compared to forecasts EPS of $0.4818 on revenue of $5.88B.
Bayer AG PK had beat expectations on Tuesday, March 1, 2022 with first quarter EPS of $0.351 on revenue of $12.39B, compared to forecast for EPS of $0.2821 on revenue of $12.04B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar